5-methoxysaccharin | 29083-17-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 5-methoxysaccharin
• 英文别名: 5-methoxy-1,1-dioxo-1,2-benzothiazol-3-one
• CAS: 29083-17-8
• 化学式: C₈H₇NO₄S
• mdl: MFCD11111714
• 分子量: 213.214
• InChiKey: GBYZSABEBYQOOQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  80.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-methoxysaccharin 在 甲醇 、 sodium hydroxide 、 sodium methylate 、 sodium hydride 作用下， 以 乙醇 、 甲苯 为溶剂， 反应 32.5h， 生成 methyl 4-hydroxy-6-methoxy-2-methyl-2H-1,2-benzothiazine-3-carboxylate-1,1-dioxide
  参考文献：
  名称：

  Effect of Structural Modification of Enol−Carboxamide-Type Nonsteroidal Antiinflammatory Drugs on COX-2/COX-1 Selectivity

  摘要：

  Meloxicam (5), an NSAID in the enol-carboxamide class, was developed on the basis of its antiinflammatory activity and relative safety in animal models. In subsequent screening in microsomal assays using human COX-1 and COX-2, we discovered that it possessed a selectivity profile for COX-2 superior to piroxicam and other marketed NSAIDs. We therefore embarked on a study of enol-carboxamide type compounds to determine if COX-2 selectivity and potency could be dramatically improved by structural modification. Substitution at the 6- and 7-positions of the 4-oxo-1,2-benzothiazine-3-carboxamide, alteration of the N-methyl substituent, and amide modification were all examined. In addition we explored several related systems including the isomeric 3-oxo-1,2-benzothiazine-4-carboxamides, thienothiazines, indolothiazines, benzothienothiazines, naphthothiazines, and 1,3- and 1,4-dioxoisoquinolines. While a few examples were found with greater potency in the COX-2 assay, no compound tested had a better COX-2/COX-1 selectivity profile than that of 5.

  DOI：

  10.1021/jm9607010
• 作为产物：
  描述：

  间甲基苯甲醚 在 二硫化碳 、 氯磺酸 、 氨 、 水 、 permanganate(VII) ion 作用下， 生成 5-methoxysaccharin
  参考文献：
  名称：

  Haworth; Lapworth, Journal of the Chemical Society, 1924, vol. 125, p. 1304

  摘要：

  DOI：

文献信息

• 一种苯并异噻唑和苯并噻吩的制备方法及其医药用途
  申请人：南京中医药大学

  公开号：CN113264900B

  公开（公告）日：2023-05-26

  本发明公开了一种苯并异噻唑和苯并噻吩的制备方法及其医药用途。涉及药物化学领域；本发明所述的苯并异噻唑和苯并噻吩是首类HIF‑2激动剂；相比申请人前期发现的化合物M1001，具有更好的HIF‑2激动活性，对HIF‑2下游的EPO、VGEF、Glut1、NDRG1等mRNA和蛋白的表达具有显著的增强活性，因此可以用于制备治疗和/或预防HIF‑2表达异常引起的慢性肾病/慢性肾贫血、血脂异常以及高胆固醇的药物；具有良好的产业化前景。
• Non-nucleoside reverse transcriptase inhibitors
  申请人：——

  公开号：US20030069226A1

  公开（公告）日：2003-04-10

  A compound of formula I: 1 wherein A is a connecting chain of (C 1-3 ) alkyl; B is O or S; R 1 is H, (C 1-6 ) alkyl, halo, CF 3 , or OR 1a wherein R 1a is H or (C 1-6 )alkyl; R 2 is H or Me; R 3 is H or Me; R 4 is H, (C 1-4 ) alkyl, (C 3-4 ) cycloalkyl and (C 1-4 )alkyl(C 3-7 )cycloalkyl; W is selected from 2 wherein, a) one of Y is SO 2 and the other Y is NR 5 , provided that both are not the same, wherein R 5 is H, (C 1-6 )alkyl,(C 3-6 ) cycloalkyl, the alkyl being substituted, COR 5o , COOR 5p or CONR 5q PR 5q ; and each R 8 is H, (C 1-4 ) alkyl, (C 3-6 ) cycloalkyl, or (C 1-4 ) alkyl-(C 3-6 ) cycloalkyl; or b) E is CR 8a R 8b wherein R 8a and R 8b is H, or alkyl and J is CH 2 ; or J is CR 8a R 8b and E is CH 2 , and the dotted line represents a single bond; or c) E is C(O) and J is CR 8a R 8b or J is C(O) and E is CR 8a R 8b and the dotted line represents a single bond; or d) E and J are CR 8a R 8b and the dotted line represents a double bond. Compounds of formula I have activity against HIV WT and double mutant strains.

  公式I的化合物：其中A是连接链(C1-3)烷基；B是O或S；R1是H，(C1-6)烷基，卤素，CF3或OR1a，其中R1a是H或(C1-6)烷基；R2是H或Me；R3是H或Me；R4是H，(C1-4)烷基，(C3-4)环烷基和(C1-4)烷基(C3-7)环烷基；W是从2中选择，其中， a) Y中的一个是SO2，另一个是NR5，前提是两者不相同，其中R5是H，(C1-6)烷基，(C3-6)环烷基，被取代的烷基，COR5o，COOR5po或CONR5qPR5q；每个R8是H，(C1-4)烷基，(C3-6)环烷基或(C1-4)烷基-(C3-6)环烷基；或 b) E是CR8aR8b，其中R8a和R8b是H，或烷基，J是CH2；或J是CR8aR8b，E是CH2，虚线代表单键；或 c) E是C(O)，J是CR8aR8b，或J是C(O)，E是CR8aR8b，虚线代表单键；或 d) E和J都是CR8aR8b，虚线代表双键。公式I的化合物对HIV WT和双突变株具有活性。
• [EN] BENZOTHIAZINE DIOXIDES AS ENDOTHELIN ANTAGONISTS<br/>[FR] DIOXYDES DE BENZOTHIAZINE UTILISES COMME ANTAGONISTES DE L'ENDOTHELINE
  申请人：WARNER-LAMBERT COMPANY

  公开号：WO1996026195A1

  公开（公告）日：1996-08-29

  (EN) Novel benzothiazine dioxides which are antagonists of endothelin are described, as well as novel intermediates used in their preparation, methods for the preparation, and pharmaceutical compositions of the same, which are useful in treating elevated levels of endohelin, essential renovascular malignant and pulmonary hypertension, cerebral infarction, cerebral ischemia, congestive heart failure, and subarachnoid hemorrhage.(FR) La présente invention concerne de nouveaux dioxydes de benzothiazine qui sont des antagonistes de l'endothéline, ainsi que de nouveaux intermédiaires utilisés pour leur préparation, des procédés de préparation et des compositions pharmaceutiques à base de ces nouveaux dioxydes de benzothiazine. Ces nouveaux dioxydes de benzothiazine sont utiles dans le traitement des niveaux élevés d'endothéline, de l'hypertension artérielle rénovasculaire et pulmonaire essentielle maligne, de l'infarctus cérébral, de l'insuffisance cardiaque congestive et de l'hémorragie sous-arachnoïdienne.

  描述了一种新的苯并噻唑二氧化物，它们是内皮素拮抗剂，以及用于它们的制备的新中间体，制备方法和相应的药物组成物，这些药物组成物在治疗内皮素水平升高、重要肾血管恶性和肺动脉高压、脑梗死、脑缺血、充血性心力衰竭和蛛网膜下腔出血方面有用。
• 4-Hydroxy-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxides and salts
  申请人：Boehringer Ingelheim GmbH

  公开号：US04233299A1

  公开（公告）日：1980-11-11

  Compounds of the formula ##STR1## wherein R.sub.1 is hydrogen, methyl or ethyl; R.sub.2 is methyl, ethyl or n-propyl; and Y is hydrogen, methyl, methoxy, fluorine or chlorine; and non-toxic, pharmacologically acceptable salts thereof formed with an inorganic or organic base. The compounds as well as their salts are useful as antiphlogistics.

  该公式化合物的化学式为##STR1##其中R.sub.1是氢、甲基或乙基；R.sub.2是甲基、乙基或正丙基；Y是氢、甲基、甲氧基、氟或氯；以及与无机或有机碱形成的无毒、药理学上可接受的盐。这些化合物及其盐在抗炎方面有用。
• Benzo-fused heterocyclic compounds
  申请人：AMERICAN HOME PRODUCTS CORPORATION

  公开号：EP0081955A2

  公开（公告）日：1983-06-22

  The invention concerns compounds of the formula: wherein R is mono- or dihalo, amino, nitro, cyano, hydroxy, trifluoromethyl, mercapto, lower alkyl, lower alkoxy, alkanoyl, cycloalkyl of 5-7 carbon atoms, carboxy, alkoxycarbonyl, mono- or di-lower alkyl substituted amino, alkanoylamino, lower alkyl thio, lower alkylsulfonyl, sulfamoyl, lower alkyl substituted sulfamoyl, phenyl or phenyl substituted with halo, lower alkyl, lower alkoxy, trifluoromethyl, hydroxy, amino, cyano or nitro. and A is amine selected from wherein R1 is hydrogen or R2CH2 wherein R2 is mono- or diloweralkylamino, mono- or di-N-lower alkylaminoloweral- kyl, (2-furyl)methylamino, benzylamino, lowercycloalkylamino, 1-pyrrolidinyl, 1-piperidinyl, 1-hexahydroazepinyl, 1-octahydroazocinyl, 3-thiazolidinyl, 4-morpholinyl or 4-thiomorpholinyl; R3 is hydrogen or (1-piperidinyl)methyl with the proviso that when R3 is (1-piperidinyl)methyl, R1 is hydrogen; n is 1 to 4 and the pharmacologically acceptable salts thereof; which inhibit gastric acid secretion. Processes for preparing the compounds and pharmaceutical compositions containing them are also disclosed.

  本发明涉及式中的化合物： 其中 R 是单卤或二卤、氨基、硝基、氰基、羟基、三氟甲基、巯基、低级烷基、低级烷氧基、烷酰基、5-7 个碳原子的环烷基、羧基、烷氧基羰基、单或双低级烷基取代的氨基、烷酰氨基、低级烷基硫代、低级烷基磺酰基、氨基磺酰基、低级烷基取代的氨基磺酰基、苯基或苯基取代的苯基、烷酰氨基、低级烷基硫代、低级烷基磺酰基、氨基磺酰基、低级烷基取代的氨基磺酰基、苯基或被卤素、低级烷基、低级烷氧基、三氟甲基、羟基、氨基、氰基或硝基取代的苯基。 和 A 是胺，选自 其中 R1 是氢或 R2CH2 其中 R2 是单-或稀低烷基氨基、单-或二-N-低烷基氨基低醛基、(2-呋喃基)甲基氨基、苄基氨基、低环烷基氨基、1-吡咯烷基、1-哌啶基、1-六氢氮杂卓基、1-八氢氮杂卓基、3-噻唑烷基、4-吗啉基或 4-硫代吗啉基；R3是氢或(1-哌啶基)甲基，但当R3是(1-哌啶基)甲基时，R1是氢；n是1至4及其药理上可接受的盐；这些化合物可抑制胃酸分泌。此外，还公开了制备这些化合物和含有这些化合物的药物组合物的工艺。